Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.
References
[1]
United Nations Economic and Social Commission for Asia and the Pacific. Statistical Yearbook for Asia and the Pacific; Bangkok, Thailand, 2011.
[2]
Lo, Y.R.; Nguyen, T.T.T.; Srikantiah, P.; Excler, J.L.; Ghidinelli, M.; Narain, J.P. AIDS in Asia and the Pacific. In HIV/AIDS in the Post-HAART Era: Manifestations, Treatment, and Epidemiology; Hall, J.C., Hall, B.J., Cockerell, C.J., Eds.; People’s Medical Publishing House: Shelton, CT, USA, 2011; pp. 839–864.
[3]
Srikantiah, P.; Ghidinelli, M.; Bachani, D.; Chasombat, S.; Daoni, E.; Mustikawati, D.E.; Nhan, D.T.; Pathak, L.R.; San, K.O.; Vun, M.C.; et al. Scale-up of national antiretroviral therapy programs: Progress and challenges in the Asia Pacific region. AIDS 2010, 24, S62–S71, doi:10.1097/01.aids.0000390091.45435.ea.
[4]
Joint United Nations Programme on HIV/AIDS. HIV in Asia and the Pacific: Getting to Zero; Bangkok, Thailand, 2011.
[5]
DeGruttola, V.; Smith, D.M.; Little, S.J.; Miller, V. Developing and evaluating comprehensive HIV infection control strategies: Issues and challenges. Clin. Infect. Dis. 2010, 50, S102–S107, doi:10.1086/651480.
[6]
Padian, N.S.; McCoy, S.I.; Karim, S.S.; Hasen, N.; Kim, J.; Bartos, M.; Katabira, E.; Sertozzi, S.M.; Schwartl？nder, B.; Cohen, M.S. HIV prevention transformed: The new prevention research agenda. Lancet 2011, 378, 269–278, doi:10.1016/S0140-6736(11)60877-5.
[7]
Kim, J.H.; Rerks-Ngarm, S.; Excler, J.L.; Michael, N.L. HIV vaccines: Lessons learned and the way forward. Curr. Opin. HIV AIDS 2010, 5, 428–434, doi:10.1097/COH.0b013e32833d17ac.
[8]
Excler, J.L.; Tomaras, G.D.; Russell, N.D. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr. Opin. HIV AIDS 2013. PMID: 23743791.
[9]
Punyacharoensin, N.; Viwatwongkasem, C. Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric back calculation method. AIDS 2009, 23, 1143–1152, doi:10.1097/QAD.0b013e32832baa1c.
[10]
Park, L.S.; Siraprapasiri, T.; Peerapatanapokin, W.; Manne, J.; Niccolai, L.; Kunanusont, C. HIV transmission rates in Thailand: Evidence of HIV prevention and transmission decline. J. Acquir. Immune Defic. Syndr. 2010, 54, 430–436.
[11]
Pitisuttithum, P.; Choopanya, K.; Rerks-Ngarm, S. HIV-vaccine research and development in Thailand: Evolution and challenges. Vaccine 2010, 28, B45–B49, doi:10.1016/j.vaccine.2009.08.061.
[12]
Nitayaphan, S.; Ngauy, V.; O’Connell, R.; Excler, J.L. HIV epidemic in Asia: Optimizing and expanding vaccine development. Expert Rev. Vaccines 2012, 11, 805–819, doi:10.1586/erv.12.49.
[13]
Pitisuttithum, P.; Gilbert, P.; Gurwith, M.; Heyward, W.; Martin, M.; van Griensven, F.; Hu, D.; Tappero, J.W.; Choopanya, K.; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194, 1661–1671.
[14]
Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 1–12, doi:10.1056/NEJMp0903765.
[15]
Gilbert, P.B.; Berger, J.O.; Stablein, D.; Becker, S.; Essex, M.; Hammer, S.M.; Kim, J.H.; Degruttola, V.G. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials. J. Infect. Dis. 2011, 203, 969–975, doi:10.1093/infdis/jiq152.
[16]
Pitisuttithum, P.; Rerks-Ngarm, S.; Bussaratid, V.; Dhitavat, J.; Maekanantawat, W.; Pungpak, S.; Suntharasamai, P.; Vanijanonta, S.; Nitayapan, S.; Kaewkungwal, J.; et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011, 6, e27837, doi:10.1371/journal.pone.0027837.
[17]
Robb, M.L.; Rerks-Ngarm, S.; Nitayaphan, S.; Pitisuttithum, P.; Kaewkungwal, J.; Kunasol, P.; Khamboonruang, C.; Thongcharoen, P.; Morgan, P.; Benenson, M; et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 2012, 12, 531–537.
[18]
Rerks-Ngarm, S.; Paris, R.M.; Chunsutthiwat, S.; Premsri, N.; Namwat, C.; Bowonwatanuwong, C.; Li, S.S.; Kaewkungkal, J.; Trichavaroj, R.; Churikanont, N.; et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX(R) B/E. J. Infect. Dis. 2012, 207, 1195–1205.
[19]
Haynes, B.F.; Gilbert, P.B.; McElrath, M.J.; Zolla-Pazner, S.; Tomaras, G.D.; Alam, S.M.; Evans, D.T.; Montefiori, D.C.; Karnasuta, C.; Sutthent, R.; et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366, 1275–1286, doi:10.1056/NEJMoa1113425.
[20]
Karasavvas, N.; Billings, E.; Rao, M.; Williams, C.; Zolla-Pazner, S.; Bailer, R.T.; Koup, R.A.; Madnote, S.; Arworn, D.; Shen, X.; et al. The Thai Phase III HIV Type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012, 28, 1444–1457, doi:10.1089/aid.2012.0103.
[21]
Zolla-Pazner, S.; Decamp, A.C.; Cardozo, T.; Karasavvas, N.; Gottardo, R.; Williams, C.; Morris, D.E.; Tomaras, G.; Rao, M.; Billings, E.; et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013, 8, e53629, doi:10.1371/journal.pone.0053629.
[22]
Tomaras, G.D.; Ferrari, G.; Shen, X.; Alam, S.M.; Liao, H.X.; Pollara, J.; Bonsignori, M.; Moody, M.A.; Fong, Y.; Chen, X.; et al. Vaccine induced plasma IgA specific for the C1-region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 2013, 110, 9019–9024, doi:10.1073/pnas.1301456110.
[23]
Ferrari, G.; Pollara, J.; Kozink, D.; Harms, T.; Drinker, M.; Freel, S.; Moody, M.A.; Alam, S.M.; Tomaras, G.D.; Ochsenbauer, C.; et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 2011, 85, 7029–7036, doi:10.1128/JVI.00171-11.
[24]
Rolland, M.; Edlefsen, P.T.; Larsen, B.B.; Tovanabutra, S.; Sanders-Buell, E.; Hertz, T.; Decamp, A.C.; Carrico, C.; Menis, S.; Magaret, C.A.; et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490, 417–420, doi:10.1038/nature11519.
[25]
Hertz, T.; Gartland, A.; Janes, H.; Li, S.; Fong, Y.; Tomaras, G.D.; Morris, D.; Geraghty, D.; Kijak, G.H.; Edlefsen, P.T.; et al. T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial. Retrovirology 2012, 9, O61, doi:10.1186/1742-4690-9-S2-O61.
[26]
Alam, S.M.; Liao, H.X.; Tomaras, G.D.; Bonsignori, M.; Tsao, C.Y.; Hwang, K.K.; Chen, H.; Lloyd, K.E.; Bowman, C.; Sutherland, L.; et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 2013, 87, 1554–1568.
[27]
Liao, H.X.; Tsao, C.Y.; Alam, S.M.; Muldoon, M.; Vandergrift, N.; Ma, B.J.; Lu, X.; Sutherland, L.L.; Scearce, R.M.; Bowman, C.; et al. Antigenicity and immunogenicity of transmitted/founder, consensus and chronic envelope glycoproteins of human immunodeficiency virus Type 1. J. Virol. 2013, 87, 4185–4201, doi:10.1128/JVI.02297-12.
[28]
Barouch, D.H.; O’Brien, K.L.; Simmons, N.L.; King, S.L.; Abbink, P.; Maxfield, L.F.; Sun, Y.H.; la Porte, A.; Riggs, A.M.; Lynch, D.M.; et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 2010, 16, 319–323, doi:10.1038/nm.2089.
[29]
Santra, S.; Liao, H.X.; Zhang, R.; Muldoon, M.; Watson, S.; Fischer, W.; Theiler, J.; Szinger, J.; Balachandran, H.; Buzby, A.; et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 2010, 16, 324–328, doi:10.1038/nm.2108.
[30]
Letourneau, S.; Im, E.J.; Mashishi, T.; Brereton, C.; Bridgeman, A.; Yang, H.; Dorrell, L.; Dong, T.; Korber, B.; McMichael, A.J.; et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2, e984.
[31]
Liu, L.; Qiu, C.; Huang, Y.; Xu, J.; Shao, Y. Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virol. Sin. 2013, 28, 109–115, doi:10.1007/s12250-013-3303-z.
[32]
Shao, Y.; Li, T.; Liu, Y.; Xu, J. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in Phase I clinical trial. AIDS. Res. Hum. Retroviruses 2010, 26, A-1-A-184.
[33]
Gouws, E.; Cuchi, P. Focusing the HIV response through estimating the major modes of HIV transmission: A multi-country analysis. Sex. Transm. Infect. 2012, 88, i76–i85, doi:10.1136/sextrans-2012-050719.
[34]
Beyrer, C.; Baral, S.D.; van Griensven, F.; Goodreau, S.M.; Chariyalertsak, S.; Wirtz, A.L.; Brookmeyer, R. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012, 380, 367–377, doi:10.1016/S0140-6736(12)60821-6.
[35]
Van Griensven, F.; de Lind van Wijngaarden, J.W. A review of the epidemiology of HIV infection and prevention responses among MSM in Asia. AIDS 2010, 24, S30–S40, doi:10.1097/01.aids.0000390087.22565.b4.
[36]
Van Griensven, F.; Thienkrua, W.; McNicholl, J.; Wimonsate, W.; Chaikummao, S.; Chonwattana, W.; Varangrat, A.; Sirivongrangson, P.; Mock, P.A.; Akarasewi, P.; Tappero, J.W. Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Bangkok, Thailand. AIDS 2013, 27, 825–832, doi:10.1097/QAD.0b013e32835c546e.
[37]
Shao, Y.; Williamson, C. The HIV-1 epidemic: Low- to middle-income countries. Cold Spring Harb. Perspect. Med. 2012, 2, a007187, doi:10.1101/cshperspect.a007187.
[38]
Sharma, M.; Oppenheimer, E.; Saidel, T.; Loo, V.; Garg, R. A situation update on HIV epidemics among people who inject drugs and national responses in south-east Asia region. AIDS 2009, 23, 1405–1413, doi:10.1097/QAD.0b013e32832bd7c9.
[39]
Dutta, A.; Wirtz, A.L.; Baral, S.; Beyrer, C.; Cleghorn, F.R. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr. Opin. HIV AIDS 2012, 7, 362–368, doi:10.1097/COH.0b013e328354a0b5.
[40]
Hemelaar, J.; Gouws, E.; Ghys, P.D.; Osmanov, S. Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 2011, 25, 679–689, doi:10.1097/QAD.0b013e328342ff93.
[41]
Merati, T.P.; Ryan, C.E.; Spelmen, T.; Wirawan, D.N.; Bakta, I.M.; Otto, B.; Oelrichs, R.B.; Crowe, S.M. CRF01_AE dominates the HIV-1 epidemic in Indonesia. Sex. Health 2012, 9, 414–421, doi:10.1071/SH11121.
[42]
Zolfo, M.; Schapiro, J.M.; Phan, V.; Koole, O.; Thai, S.; Vekemans, M.; Fransen, K.; Lynen, L. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. AIDS. Res. Hum. Retroviruses 2011, 27, 727–735, doi:10.1089/aid.2010.0037.
[43]
Nouhin, J.; Donchai, T.; Hoang, K.T.; Ken, S.; Kamkorn, J.; Tran, T.; Ayouba, A.; Peeters, M.; Chaix, M.L.; Lien, T.X.; et al. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study. Infect. Genet. Evol. 2011, 11, 38–43, doi:10.1016/j.meegid.2010.10.014.
[44]
Lazaro, E.; Tram, L.T.; Bellecave, P.; Guidicelli, G.L.; Anies, G.; Thu, H.H.; Debelleix, M.P.; Vray, M.; Recordon-Pinson, P.; Taupin, J.L.; et al. Molecular characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, and impact of T-cell epitope mutations on HLA recognition (ANRS 12159). PLoS One 2011, 6, e26244, doi:10.1371/journal.pone.0026244.
[45]
Oyomopito, R.A.; Li, P.C.; Sungkanuparph, S.; Phanuphak, P.; Tee, K.K.; Sirisanthana, T.; Kantipong, P.; Oka, S.; Lee, C.K.; Kamarulzaman, A.; et al. Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B. J. Acquir. Immune Defic. Syndr. 2013, 62, 293–300, doi:10.1097/QAI.0b013e31827a2e8f.
[46]
Lau, K.A.; Wang, B.; Miranda-Saksena, M.; Boadle, R.; Kamarulzaman, A.; Ng, K.P.; Saksena, N.K. Evidence for possible biological advantages of the newly emerging HIV-1 circulating recombinant form from Malaysia—CRF33_01B in comparison to its progenitors-CRF01_AE and subtype B. Curr. HIV Res. 2010, 8, 259–271, doi:10.2174/157016210791111151.
[47]
Sahbandar, I.N.; Takahashi, K.; Djoerban, Z.; Firmansyah, I.; Naganawa, S.; Motomura, K.; Sato, H.; Kitamura, K.; Pohan, H.T.; Sato, S. Current HIV type 1 molecular epidemiology profile and identification of unique recombinant forms in Jakarta, Indonesia. AIDS Res. Hum. Retroviruses 2009, 25, 637–646, doi:10.1089/aid.2008.0266.
[48]
Kijak, G.H.; Tovanabutra, S.; Rerks-Ngarm, S.; Nitayaphan, S.; Eamsila, C.; Kunasol, P.; Khamboonruang, C.; Thongcharoen, P.; Namwat, C.; Premsri, N.; et al. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J. Virol. 2013, 87, 7265–7281, doi:10.1128/JVI.03070-12.
[49]
Chariyalertsak, S.; Kosachunhanan, N.; Saokhieo, P.; Songsupa, R.; Wongthanee, A.; Chariyalertsak, C.; Visarutratana, S.; Beyrer, C. HIV incidence, risk factors, and motivation for biomedical intervention among gay, bisexual men, and transgender persons in Northern Thailand. PLoS One 2011, 6, e24295, doi:10.1371/journal.pone.0024295.
[50]
Robb, M. Viral dynamics and immune response in acute infection and their impact on viral set-point. Abstract PL02.02. In Presented at: AIDS Vaccine 2012, Boston, MA, USA, 9–12 September 2012.
[51]
Department of Health, Ministry of Health. Results of HIV Sero-Surveillance 2011, Myanmar; National AIDS Programme: Naypyidaw, Myanmar, 2012.
[52]
Department of Health, Ministry of Health. Progress Report 2011. National Strategic Plan for HIV AIDS in Myanmar, National AIDS Programme; Naypyidaw, Myanmar, 2011.
[53]
Williams, B.; Baker, D.; Bühler, M.; Petrie, C. Increase coverage of HIV and AIDS services in Myanmar. Confl. Health. 2008, 2, 3, doi:10.1186/1752-1505-2-3.
[54]
Williams, C.T.; Liu, W.; Levy, J.A. Crossing over: Drug network characteristics and injection risk along the China-Myanmar border. AIDS Behav. 2011, 15, 1011–1016, doi:10.1007/s10461-010-9764-2.
[55]
Liu, J.; Jia, Y.; Xu, Q.; Zheng, Y.T.; Zhang, C. Phylodynamics of HIV-1 unique recombinant forms in China-Myanmar border: Implication for HIV-1 transmission to Myanmar from Dehong, China. Infect. Genet. Evol. 2012, 12, 1944–1948, doi:10.1016/j.meegid.2012.08.001.
[56]
Pang, W.; Zhang, C.; Duo, L.; Zhou, Y.H.; Yao, Z.H.; Liu, F.L.; Li, H.; Tu, Y.Q.; Zheng, Y.T. Extensive and complex HIV-1 recombination between B’, C and CRF01_AE among IDUs in South-East Asia. AIDS 2012, 26, 1121–1129, doi:10.1097/QAD.0b013e3283522c97.
[57]
Shang, H.; Xu, J.; Han, X.; Li, J.S.; Arledge, K.C.; Zhang, L. HIV prevention: Bring safe sex to China. Nature 2012, 485, 576–577, doi:10.1038/485576a.
[58]
Lou, J.; Wu, J.; Chen, L.; Ruan, Y.; Shao, Y. A sex-role-preference model for HIV transmission among men who have sex with men in China. BMC Public Health 2009, 9, S10, doi:10.1186/1471-2458-9-S1-S10.
[59]
Mi, G.; Wu, Z. A review of studies on sero-sorting among HIV positive men who have sex with men. Chin. J. AIDS STD 2010, 16, 201–203.
[60]
Wu, Z.; Xu, J.; Liu, E.; Mao, Y.; Xiao, Y.; Sun, X.; Liu, Y.; Jiang, Y.; McGoogan, J.M.; Dou, Z.; et al. HIV and syphilis prevalence among men who have sex with men: A cross-sectional survey of 61 cities in China. Clin. Infect. Dis. 2013, 57, 298–309, doi:10.1093/cid/cit210.
[61]
Tang, W.M.; Ding, J.P.; Yan, H.J.; Xuan, X.P.; Yang, H.T.; Zhao, J.K. Sexual behaviors and HIV/syphilis infection among men who have sex with men: A meta-analysis of data collected between 2001 and 2006 in the Chinese mainland. Chin. J. AIDS STD 2008, 14, 471–488.
[62]
Chow, E.P.; Wilson, D.P.; Zhang, L. What is the potential for bisexual men in China to act as a bridge of HIV transmission to the female population? Behavioural evidence from a systematic review and meta-analysis. BMC Infect. Dis. 2011, 11, 242, doi:10.1186/1471-2334-11-242.
[63]
He, Q.; Peng, W.J.; Zhang, J.Q.; Wang, B.X.; Wang, J. Prevalence of unprotected anal intercourse and unprotected vaginal intercourse among HIV-positive men who have sex with men in China: A meta-analysis. Sex. Transm. Infect. 2012, 88, 229–233, doi:10.1136/sextrans-2011-050230.
[64]
Yun, K.; Xu, J.J.; Reilly, K.H.; Zhang, J.; Jiang, Y.J.; Wang, N.; Shang, H. Prevalence of bisexual behaviour among bridge population of men who have sex with men in China: A meta-analysis of observational studies. Sex. Transm. Infect. 2011, 87, 563–570, doi:10.1136/sextrans-2011-050079.
[65]
Chow, E.P.; Wilson, D.P.; Zhang, L. Estimating HIV incidence among female partners of bisexual men in China. Int. J. Infect. Dis. 2012, 16, e312–e320, doi:10.1016/j.ijid.2012.01.012.
[66]
Li, D.; Jia, Y.; Ruan, Y.; Liu, Y.; Li, Q.; Liang, H.; Zhou, Z.; Luo, F.; Zhang, X.; Jiang, S.; et al. Correlates of incident infections for HIV, syphilis, and hepatitis B virus in a cohort of men who have sex with men in Beijing. AIDS Patient Care STDS 2010, 24, 595–602, doi:10.1089/apc.2010.0083.
[67]
Xu, J.; An, M.; Han, X.; Jia, M.; Ma, Y.; Zhang, M.; Hu, Q.; Chu, Z.; Zhang, J.; Jiang, Y.; et al. Prospective cohort study of HIV incidence and molecular characteristics of HIV among men who have sex with men (MSM) in Yunnan Province, China. BMC Infect. Dis. 2013, 13, 3, doi:10.1186/1471-2334-13-3.
[68]
Yang, H.; Hao, C.; Huan, X.; Yan, H.; Guan, W.; Xu, X.; Zhang, M.; Tang, W.; Wang, N.; Lau, J.T. HIV incidence and associated factors in a cohort of men who have sex with men in Nanjing, China. Sex. Transm. Dis. 2010, 37, 208–213.
[69]
Xu, J.J.; Zhang, M.; Brown, K.; Reilly, K.; Wang, H.; Hu, Q.; Ding, H.; Chu, Z.; Bice, T.; Shang, H. Syphilis and HIV seroconversion among a 12-month prospective cohort of men who have sex with men in Shenyang, China. Sex. Transm. Dis. 2010, 37, 432–439.
[70]
Zhang, Y.; Lu, L.; Ba, L.; Liu, L.; Yang, L.; Jia, M.; Wang, H.; Fang, Q.; Shi, Y.; Yan, W.; et al. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med. 2006, 3, e443, doi:10.1371/journal.pmed.0030443.
[71]
Ye, J.; Xin, R.; Yu, S.; Bai, L.; Wang, W.; Wu, T.; Su, X.; Lu, H.; Pang, X.; Yan, H.; et al. Phylogenetic and temporal dynamics of human immunodeficiency virus type 1 CRF01_AE in China. PLoS One 2013, 8, e54238.
[72]
An, M.; Han, X.; Xu, J.; Xu, J.; Chu, Z.; Jia, M.; Wu, H.; Lu, L.; Takebe, Y.; Shang, H. Reconstituting the epidemic history of HIV strain CRF01_AE among men who have sex with men (MSM) in Liaoning, northeastern China: Implications for the expanding epidemic among MSM in China. J. Virol. 2012, 86, 12402–12406, doi:10.1128/JVI.00262-12.
[73]
Su, Y.Z.; Ma, Y.L.; Jia, M.H.; He, X.; Yang, L.; Cheng, C.L.; Chen, M.; Shi, Y.H.; Chen, L.; Chen, H.C.; et al. Update on diversity and distribution of HIV-1 subtypes in Yunnan province. Epidemiol. Infect. 2013, 14, 1–10.
[74]
Chen, M.; Ma, Y.; Duan, S.; Xing, H.; Yao, S.; Su, Y.; Luo, H.; Yang, L.; Chen, H.; Fu, L.; et al. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: A hot area of viral recombination in China. BMC Infect. Dis. 2012, 12, 382, doi:10.1186/1471-2334-12-382.
[75]
Yao, X.; Wang, H.; Yan, P.; Lu, Y.; Lin, H.; Chen, L.; Ng, J.; Lau, E.; Liu, L.; Wu, J.; et al. Rising epidemic of HIV-1 infections among general populations in Fujian, China. J. Acquir. Immune Defic. Syndr. 2012, 60, 328–335, doi:10.1097/QAI.0b013e31824f19f5.
[76]
Sun, X.G.; Xing, H.; Li, Z.J.; Cheng, C.L.; Zhang, X.H.; Shen, L.M.; He, X. Distribution of HIV-1 subtype and its relationship with HIV/AIDS epidemic in Guizhou province. Zhonghua Liu Xing Bing Xue Za Zhi 2011, 32, 689–692.
[77]
Li, L.; Liang, S.; Chen, L.; Liu, W.; Li, H.; Liu, Y.; Bao, Z.; Wang, Z.; Zhuang, D.; Liu, S.; et al. Genetic characterization of 13 subtype CRF01_AE near full-length genomes in Guangxi, China. AIDS Res. Hum. Retroviruses 2010, 26, 699–704, doi:10.1089/aid.2010.0026.
[78]
Cheng, C.L.; Feng, Y.; He, X.; Lin, P.; Liang, S.J.; Yi, Z.Q.; He, J.M.; Hu, Y.Y.; Xing, H.; Fan, Y.; et al. Genetic characteristics of HIV-1 CRF01_AE strains in four provinces, southern China. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30, 720–725.
[79]
Chen, J.H.; Wong, K.H.; Li, P.; Chan, K.C.; Lee, M.P.; Lam, H.Y.; Cheng, V.C.; Yuen, K.Y.; Yam, W.C. Molecular epidemiological study of HIV-1 CRF01_AE transmission in Hong Kong. J. Acquir. Immune Defic. Syndr. 2009, 51, 530–535, doi:10.1097/QAI.0b013e3181aac516.
[80]
Zheng, Y.; Lu, H.; Jiang, X.; Pang, M.; Farthing, C. Epidemiology of HIV infection among men having sex with men in Shanghai, China. Southeast Asian J. Trop. Med. Public Health 2012, 43, 1304–1306.
[81]
Kondo, M.; Lemey, P.; Sano, T.; Itoda, I.; Yoshimura, Y.; Sagara, H.; Tachikawa, N.; Yamanaka, K.; Iwamuro, S.; Matano, T.; et al. Emergence in Japan of an HIV-1 variant associated with MSM transmission in China: First indication for the international dissemination of the Chinese MSM lineage. J. Virol. 2013, 87, 5351–5361, doi:10.1128/JVI.02370-12.
[82]
Wang, W.; Meng, Z.; Zhou, M.; Guo, C.; Zhang, F.; Xu, J.; Zhang, X. Near full-length sequence analysis of two new HIV type 1 unique (CRF01_AE/B) recombinant forms among men who have sex with men in China. AIDS Res. Hum. Retroviruses 2012, 28, 411–417, doi:10.1089/aid.2011.0196.
[83]
Wu, J.; Meng, Z.; Xu, J.; Lei, Y.; Jin, L.; Zhong, P.; Han, R.; Su, B. New emerging recombinant HIV-1 strains and close transmission linkage of HIV-1 strains in the Chinese MSM population indicate a new epidemic risk. PLoS One 2013, 8, e54322.
[84]
Stover, J.; Bollinger, L.; Avila, C. Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res. Treat. 2011, 2011, 738271–738277.
[85]
Schwartl？nder, B.; Stover, J.; Hallett, T.; Atun, R.; Avila, C.; Gouws, E.; Bartos, M.; Ghys, P.D.; Opuni, M.; Barr, D.; et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011, 377, 2031–2041, doi:10.1016/S0140-6736(11)60702-2.
[86]
IAVI Insights. The potential impact of an AIDS vaccine in low- and middle-Income countries. Available online: http://www.iavi.org/ (accessed on 29 May 2012).
[87]
IAVI Insights. China: Estimating the impact of an AIDS vaccine. Available online: http://www.iavi.org/ (accessed on 31 August 2012).
[88]
Andersson, K.M.; Stover, J. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 2011, 9, 6092–6099, doi:10.1016/j.vaccine.2011.06.060.
[89]
Nagelkerke, N.J.; Hontelez, J.A.; de Vlas, S.J. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine 2011, 29, 6079–6085, doi:10.1016/j.vaccine.2011.06.048.
[90]
Jack, A. GSK signs lifetime deal with Brazil for pneumococcal vaccine. Financial Times, Available online: http://www.ft.com/ (accessed on 28 September 2009).
[91]
HIV/AIDS Research Highlights. Available online: http://www.niaid.nih.gov/topics/hivaids/research/vaccines/clinical/Pages/highlights.aspx/ (accessed on 25 July 2013).
[92]
Excler, J.L.; Pitisuttithum, P.; Rerks-Ngarm, S.; Shao, Y.; Zhang, L.; Tamashiro, H.; Osmanov, S.; WHO-UNAIDS Regional Consultation. Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J. Trop. Med. Public Health 2008, 39, 766–784.
[93]
Kent, S.J.; Cooper, D.A.; Vun, M.C.; Shao, Y.; Zhang, L.; Ganguly, N.; Bela, B.; Tamashiro, H.; Ditangco, R.; Rerks-Ngarm, S.; et al. AIDS vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccines. PLoS Med. 2010, 7, e1000331, doi:10.1371/journal.pmed.1000331.
[94]
Rerks-Ngarm, S.; Pitisuttithum, P.; Ganguly, N.; Zhang, L.; Tamashiro, H.; Cooper, D.A.; Vun, M.C.; Bela, B.; Ditangco, R.; van Kinh, N.; et al. Defining the objectives of the AIDS vaccine for Asia network: Report of the WHO–UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr. Opin. HIV AIDS 2010, 5, 435–452, doi:10.1097/COH.0b013e32833c95c1.
[95]
Pitisuttithum, P.; Rerks-Ngarm, S.; Chiu, J.; Kim, J.; Benenson, M.; Kent, S.J.; Tamashiro, H.; Manrique, A.; Bernstein, A.; Goyal, R.; et al. Accelerating the development of an AIDS vaccine: The AIDS vaccine for asia network (AVAN). Southeast Asian J. Trop. Med. Public Health 2011, 42, 1130–1147.
[96]
Boily, M.C.; Baggaley, R.F.; Wang, L.; Masse, B.; White, R.G.; Hayes, R.J.; Alary, M. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect. Dis. 2009, 9, 118–129, doi:10.1016/S1473-3099(09)70021-0.
[97]
Shaw, G.M.; Hunter, E. HIV transmission. Cold Spring Harb. Perspect. Med. 2012, doi:10.1101/cshperspect.a006965.
[98]
The Joint United Nations Programme on HIV/AIDS, Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. UNAIDS, Geneva, Switzerland, 2012.
[99]
Zhou, Y.H.; Liu, F.L.; Yao, Z.H.; Duo, L.; Li, H.; Sun, Y.; Zheng, Y.T. Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS One 2011, 6, e16349.
[100]
Lucas, G.M.; Beauchamp, G.; Aramrattana, A.; Shao, Y.; Liu, W.; Fu, L.; Jackson, J.B.; Celentano, D.D.; Richardson, P.; Metzger, D.; HPTN 058 study group. Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int. J. Drug Policy 2012, 23, 162–165.
[101]
Neogi, U.; Sood, V.; Banerjee, S.; Ghosh, N.; Verma, S.; Samrat, S.; Sharma, Y.; Saxena, A.; Husain, S.; Ramachandran, V.G.; et al. Global HIV-1 molecular epidemiology with special reference to genetic analysis of HIV-1 subtypes circulating in North India: Functional and pathogenic implications of genetic variation. Indian J. Exp. Biol. 2009, 47, 424–431.
[102]
Bar, K.J.; Li, H.; Chamberland, A.; Tremblay, C.; Routy, J.P.; Grayson, T.; Sun, C.; Wang, S.; Learn, G.H.; Morgan, C.J.; et al. Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users. J. Virol. 2010, 84, 6241–6247, doi:10.1128/JVI.00077-10.
[103]
Padian, N.S.; McCoy, S.I.; Manian, S.; Wilson, D.; Schwartl？nder, B.; Bertozzi, S.M. Evaluation of large-scale combination HIV prevention programs: Essential issues. J. Acquir. Immune Defic. Syndr. 2011, 58, e23–e28, doi:10.1097/QAI.0b013e318227af37.
[104]
Kim, S.C.; Becker, S.; Dieffenbach, C.; Hanewall, B.S.; Hankins, C.; Lo, Y.R.; Mellors, J.W.; O’Reilly, K.; Paxton, L.; Roffenbender, J.S.; et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: Challenges and opportunities. J. Int. AIDS Soc. 2010, 13, 24, doi:10.1186/1758-2652-13-24.
[105]
Granich, R.; Lo, Y.R.; Suthar, A.; Vitoria, M.; Baggaley, R.; Obermeyer, C.M.; McClure, C.; Souteyrand, Y.; Perriens, J.; Kahn, J.G.; et al. Harnessing the prevention benefits of antiretroviral treatment to address HIV and tuberculosis. Curr. HIV Res. 2011, 9, 355–366, doi:10.2174/157016211798038551.
[106]
Cohen, M.S.; Holmes, C.; Padian, N.; Wolf, M.; Hirnschall, G.; Lo, Y.R.; Goosby, E. HIV treatment as prevention: How scientific discovery occurred and translated rapidly into policy for the global response. Health Aff. (Millwood) 2012, 31, 1439–1449.
[107]
Krakower, D.; Mayer, K.H. Promising prevention approaches: Tenofovir gel and prophylactic use of antiretroviral medications. Curr. HIV/AIDS Rep. 2011, 8, 241–248.
[108]
Grant, R.M.; Lama, J.R.; Anderson, P.L.; McMahan, V.; Liu, A.Y.; Vargas, L.; Goicochea, P.; Casapía, M.; Guanira-Carranza, J.V.; Ramirez-Cardich, M.E.; et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010, 363, 2587–2599, doi:10.1056/NEJMoa1011205.
[109]
Wheelock, A.; Eisingerich, A.B.; Ananworanich, J.; Gomez, G.B.; Hallett, T.B.; Dybul, M.R.; Piot, P. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One 2013, 8, e54288.
[110]
Zhou, F.; Gao, L.; Li, S.; Li, D.; Zhang, L.; Fan, W.; Yang, X.; Yu, M.; Xiao, D.; Yan, L.; et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One 2012, 7, e32329.
[111]
Grant, R.; McMahan, V.; Amico, R.; et al. Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. Abstract WELBC02. In Presented at Proceedings of 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 30 June–3 July 2013.
[112]
Excler, J.L.; Rida, W.; Priddy, F.; Gilmour, J.; McDermott, A.B.; Kamali, A.; Anzala, O.; Mutua, G.; Sanders, E.J.; Koff, W.; et al. AIDS vaccines and preexposure prophylaxis: Is synergy possible? AIDS Res. Hum. Retroviruses 2011, 27, 669–680, doi:10.1089/aid.2010.0206.
[113]
Janes, H.; Gilbert, P.; Buchbinder, S.; Kublin, J.; Sobieszczyk, M.E.; Hammer, S.M. In pursuit of an HIV vaccine: Designing efficacy trials in the context of partially effective non-vaccine prevention modalities. AIDS Res. Hum. Retroviruses 2013, doi:10.1089/aid.2012.0385.
[114]
Jaspan, H.B.; Cunningham, C.K.; Tucker, T.J.; Wright, P.F.; Self, S.G.; Sheets, R.L.; Rogers, A.S.; Bekker, L.G.; Wilson, C.M.; Duerr, A.; et al. Inclusion of adolescents in preventive HIV vaccine trials: Public health policy and research design at a crossroads. J. Acquir. Immune Defic. Syndr. 2008, 47, 86–92, doi:10.1097/QAI.0b013e31815d2f27.
[115]
Silbermann, B.; Tod, M.; Desaint, C.; Pialoux, G.; Petitprez, K.; Slama, L.; Poncelet, H.; Moreau, C.; Mazarin, V.; Heshmati, F.; et al. Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res. Hum. Retroviruses 2008, 24, 1445–1448, doi:10.1089/aid.2008.0107.
[116]
Van Braeckel, E.; Koutsoukos, M.; Bourguignon, P.; Clement, F.; McNally, L.; Leroux-Roels, G. Vaccine-induced HIV seropositivity: A problem on the rise. J. Clin. Virol. 2011, 50, 334–337, doi:10.1016/j.jcv.2011.01.003.
[117]
Cooper, C.J.; Metch, B.; Dragavon, J.; Coombs, R.W.; Baden, L.R.; NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010, 304, 275–283.
[118]
Penezina, O.; Clapham, D.; Collins, J.; Kovalenko, V.; Krueger, N.; Rodriguez-Chavez, I.R.; Busch, M.P.; Levin, A.E. New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants. Retrovirology 2012, 9, P120.
[119]
Newman, P.A.; Roungprakhon, S.; Tepjan, S.; Yim, S.; Walisser, R. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob. Public Health 2012, 7, 1009–1024, doi:10.1080/17441692.2012.692388.
[120]
Newman, P.A.; Roungprakhon, S.; Tepjan, S.; Yim, S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010, 28, 958–964, doi:10.1016/j.vaccine.2009.10.142.
